Co-Diagnostics (HAM:C970) Marketable Securities: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:C970 Co-Diagnostics Inc HAM:C970
63 GF Score
Price €5.55
GF Value €4.78
! 6 Warning Signs
View Full Analysis

What is Co-Diagnostics Marketable Securities?

Co-Diagnostics HAM:C970 63 Marketable Securities is €0.00 Mil as of Mar. 2026. GuruFocus rates HAM:C970 with a GF Score™ of 63/100 and a GF Value™ of €4.78. The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Co-Diagnostics's Marketable Securities for the quarter that ended in Mar. 2026 was €0.00 Mil.

Co-Diagnostics's annual Marketable Securities declined from Dec. 2023 (€40.01 Mil) to Dec. 2024 (€25.61 Mil) and declined from Dec. 2024 (€25.61 Mil) to Dec. 2025 (€0.00 Mil).

Co-Diagnostics  (HAM:C970) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Co-Diagnostics Marketable Securities Related Terms

Co-Diagnostics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Co-Diagnostics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Co-Diagnostics Marketable Securities Chart

Co-Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.11 55.03 40.01 25.61 0.00

Co-Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.11 1.95 0.00 0.00 0.00
HAM:C970
63GF Score
Co-Diagnostics Inc HAM:C970
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Co-Diagnostics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
Co-Diagnostics (HAM:C970) has a Marketable Securities of €0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Co-Diagnostics and its competitors.
Is Co-Diagnostics' Marketable Securities too high?
Co-Diagnostics' current Marketable Securities is €0.00 Mil. Overall, Co-Diagnostics has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Marketable Securities compare to ALRTF and SINT?
Co-Diagnostics' Marketable Securities of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Co-Diagnostics and its competitors. Co-Diagnostics's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current Marketable Securities of €0.00 Mil. The stock's GF Value™ is €4.78, compared to a current price of €5.55 — trading 16.1% above its estimated fair value. The current Marketable Securities is €0.00 Mil. Co-Diagnostics' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current Marketable Securities is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Co-Diagnostics (HAM:C970) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued. The current stock price of €5.55 is trading 16.1% above its estimated GF Value™ of €4.78.

Key valuation signals for HAM:C970:

  • Marketable Securities: €0.00 Mil
  • GF Value™: €4.78 vs. price of €5.55 (16.1% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Co-Diagnostics Business Description

Other Exchanges CODX:USA0A50:UK
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score

Get the complete analysis for HAM:C970

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.55
Price
€4.78
GF Value